EXE OE (i treertnermic intraperitoneal chemoterapy (HIPEC) and synchronous cytoreductive surgery smo 2014 iepasen Ueto de Gave f0r peritoneal carcinomatosis from gastric cancer results from a single center experience re our im: to assess the eary- and long-term outcomes of patents undergoing neoadjwant chemotherapy followed by combined cytoreducive surgery (eluding (sub)total iistrectomy) and HIPE for peritoneal carcinomatosis arising rom east cancer Methods: retrospective study of al cases of patients treated for peritoneal carcinomatosis rom gastric cancer (adenocatlnom) nour isto from 2008 to 2012, clusion enter: presence of visceral or extra-abdomial metastasis, poor performance status (ECOG > 2) and Peritoneal Carinomatesis index (PO) score 212 ataagnoste pe treatment aparoscopy. = pests witha eden ove lowe of 17 months age at HIPEC (years) 438 X iat y mis 8 ! ¢ Berets Sine aoe a ‘ mannan! 4 es ues : : = I = ues a ecdame Soo a Sas scneeenns ome | ne ee ele edi RS:20 months Wedon 05:21 months Modan 35:34 mont [pathological stage (n / 6) i aa me 212% | stor sul comaleations Caven$:1pten/16; Cavin 3: patent 16; days orally: a YS | conloion: combine ncaa and fered ug ssocated with HPCC safes nd sf protocol wth act ym aocesatcupsryimean) 36°" | mobidity and mortality in experienced centers. Considering the fact thatthe median overall survival in gastric cancer patients wi Setar 8. | Potenestcrenomatssis80monts ns onvies esmen slows to xr beter aucomes seed pens